Best Practices for Microbial Challenge In-Use Studies to Evaluate the Microbial Growth Potential of Parenteral Biological Products; Industry and Regulatory Considerations

References

1. 1.↵
   1. Nejadnik M. R.,
   2. Randolph T. W.,
   3. Volkin D. B.,
   4. Schöneich C.,
   5. Carpenter J. F.,
   6. Crommelin D. J. A.,
   7. Jiskoot W.

   Postproduction Handling and Administration of Protein Pharmaceuticals and Potential Instability Issues. J. Pharm. Sci. 2018, 107 (8), 2013–2019.

   OpenUrl
2. 2.↵
   1. Jameel F.,
   2. Skoug J. W.,
   3. Nesbitt R. R.

   1. Gupta S.,
   2. Alaarg A.,
   3. Wu Z.,
   4. Lu X.,
   5. Garripelli V.,
   6. Dong H.,
   7. Sawilla S.,
   8. Patel B.,
   9. Schroeder R.

   Chapter 18: Design of Clinical In-Use studies. In Development of Biopharmaceutical Drug-Device Products, 1st ed.; Jameel F., Skoug J. W., Nesbitt R. R., Eds.; Springer International Publishing: Cham, Switzerland, 2020; pp 431–459.
3. 3.↵
   1. Ricci M. S.,
   2. Frazier M.,
   3. Moore J.,
   4. Cromwell M.,
   5. Galush W. J.,
   6. Patel A. R.,
   7. Adler M.,
   8. Altenburger U.,
   9. Grauschopf U.,
   10. Goldbach P.,
   11. Fast J. L.,
   12. Krämer I.,
   13. Mahler H. C.

   In-Use Physicochemical and Microbiological Stability of Biological Parenteral Products. Am. J. Health-Syst. Pharm. 2015, 72 (5), 396–407.

   OpenUrlFREE Full Text
4. 4.↵
   1. Sarakbi I.,
   2. Federici M.,
   3. Krämer I.

   Viability of Microorganisms in Novel Chemical and Biopharmaceutical Anticancer Drug Solutions. Eur. J. Parenter. Pharm. Sci. 2015, 20 (1), 5–12.

   OpenUrl
5. 5.↵
   U.S. Pharmacopeial Convention. General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. In USP 43–NF 38, USP: Rockville, MD, 2008.
6. 6.↵
   1. Hu Q.,
   2. Wu J.,
   3. Chu K. P.,
   4. Cao Y.,
   5. Kamen D.,
   6. Kleppe M.,
   7. Cheng Y.,
   8. Liu D.,
   9. Shameem M.

   Characterization of Microbial Growth Potential in Antibody Drug IV Admixtures by Microbial Challenge. J. Pharm. Sci. 2023, 112 (11), 2820–2833.

   OpenUrl
7. 7.↵
   1. Metcalfe J. W.

   Microbiological Quality of Drug Products after Penetration of the Container System for Dose Preparation Prior to Patient Administration. Am. Pharm. Rev. 2009, 12 (1), 84–89.

   OpenUrl
8. 8.↵
   1. Lolas A. G.,
   2. Metcalfe J. W.

   Evaluation of the Microbial Growth Potential of Pharmaceutical Drug Products and Quality by Design. PDA J. Pharm. Sci. Technol. 2011, 65 (1), 63–70.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   U.S. Pharmacopeial Convention. General Chapter <800>Hazardous Drugs—Handling in Healthcare Settings. In USP 43–NF 38, USP: Rockville, MD, 2020.
10. 10.↵
    International Conference for Harmonisation. Quality Guideline Q8(R2): Pharmaceutical Development. ICH Web site. https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf (accessed October 2022).
11. 11.↵
    International Conference for Harmonisation. Quality Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. ICH Web site. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf (accessed October 2022).
12. 12.↵
    International Conference for Harmonisation. Quality Guideline Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. ICH Web site. https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf (accessed October 2022).
13. 13.↵
    1. Bennett S. N.,
    2. McNeil M. M.,
    3. Bland L. A.,
    4. Arduino M. J.,
    5. Villarino M. E.,
    6. Perrotta D. M.,
    7. Burwen D. R.,
    8. Welbel S. F.,
    9. Pegues D. A.,
    10. Stroud L.,
    11. Zeitz P. S.,
    12. Jarvis W. R.

    Postoperative Infections Traced to Contamination of an Intravenous Anesthetic, Propofol. N. Engl. J. Med. 1995, 333 (3), 147–154.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Mattner F.,
    2. Gastmeier P.

    Bacterial Contamination of Multiple-Dose Vials: A Prevalence Study. Am. J. Infect. Control 2004, 32 (1), 12–16.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Manchikanti L.,
    2. Falco F. J. E.,
    3. Benyamin R. M.,
    4. Caraway D. L.,
    5. Helm Ii S.,
    6. Wargo B. W.,
    7. Hansen H.,
    8. Parr A. T.,
    9. Singh V.,
    10. Hirsch J. A.

    Assessment of Infection Control Practices for Interventional Techniques: A Best Evidence Synthesis of Safe Injection Practices and Use of Single-Dose Medication Vials. Pain Phys. 2012, 15 (5), E573–E614.

    OpenUrl
16. 16.↵
    U.S. Food and Drug Administration. Question-Based Review (QbR) for Sterility Assurance of Terminally Sterilized Products: Frequently Asked Questions. FDA Web site. https://www.fda.gov/media/81734/download (accessed May 2023).
17. 17.↵
    U.S. Food and Drug Administration. 21CFR Part 201–Labeling, Section 201.56(a) General Requirements. U.S. Department of Health and Human Services. Government Publishing Office: Washington D.C. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201 (accessed October 2022).
18. 18.↵
    U.S. Food and Drug Administration. 21CFR Part 201–Labeling, Section 201.57(c)(3) Dosage and Administration. U.S. Department of Health and Human Services. Government Publishing Office: Washington D.C. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201 (accessed October 2022).
19. 19.↵
    U.S. Congress. United States Code: The Public Health Service, 42 U.S.C. §§ 201-291n. Library of Congress: Washington D.C. https://www.loc.gov/item/uscode1952-004042006a/ (accessed October 2022).
20. 20.↵
    U.S. Food and Drug Administration. 21CFR Part 201–Labeling, Section 201.5(g) Drugs; Adequate Directions for Use. U.S. Department of Health and Human Services. Government Publishing Office: Washington D.C. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201#p-201.5(Adequate%20directions%20for%20use (accessed October 2022).
21. 21.↵
    U.S. Food and Drug Administration. 21CFR Part 211–Current Good Manufacturing Practice for Finished Pharmaceuticals, Section 211.137 Expiration Dating. U.S. Department of Health and Human Services. Government Publishing Office: Washington D.C. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-G (accessed October 2022).
22. 22.↵
    U.S. Food and Drug Administration. 21CFR Part 211–Current Good Manufacturing Practice for Finished Pharmaceuticals, Section 211.166 Stability Testing. U.S. Department of Health and Human Services. Government Publishing Office: Washington D.C. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-I (accessed October 2022).
23. 23.↵
    U.S. Food and Drug Administration. Guidance for Industry: Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products—Content and Format, Center for Biologics Evaluation Research. U.S. Department of Health and Human Services: Rockville, MD, 2010.
24. 24.↵
    U.S. Food and Drug Administration. Guidance for Industry: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application, Center for Drug Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2018.
25. 25.↵
    U.S. Food and Drug Administration. Guidance for Industry: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well Characterized, Therapeutic, Biotechnology-Derived Products, Center for Biologics Evaluation Research. U.S. Department of Health and Human Services: Rockville, MD, 1995.
26. 26.↵
    U.S. Food and Drug Administration. Guidance for Industry: Current Good Manufacturing Practice for Phase 1 Investigational Drugs, Center for Biologics Evaluation Research. U.S. Department of Health and Human Services: Rockville, MD, 2008.
27. 27.↵
    U.S. Pharmacopeial Convention. General Chapter <51> Antimicrobial Effectiveness Testing. In USP 43–NF 38, USP: Rockville, MD, 2018.
28. 28.↵
    European Medicines Agency. Note for Guidance on Maximum Shelf-Life for Sterile Products for Human Use after First Opening or Following Reconstitution. Committee for Proprietary Medicinal Products (CPMP): London, 1998.
29. 29.↵
    Australian Government. Stability Testing for Prescription Medicines: Guidance for Sponsors on Demonstrating Stability of Medicines under Australian Conditions. 14.2, General Guidance. Australian Government, Department of Health and Aged Care, Therapeutic Goods Administration: https://www.tga.gov.au/resources/resource/guidance/stability-testing-prescription-medicines/142-general-guidance (accessed May 2023).
30. 30.↵
    Health Canada. Guidance Document: Product Monograph (2020). 11. Storage, Stability and Disposal. Government of Canada: Ottawa, ON: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/product-monograph/guidance-document-product-monograph-2020.html (accessed May 2023).
31. 31.↵
    1. Hughes P.

    Regulatory Perspectives In-Use Storage of Biologic Products: Phase Appropriate Microbial Challenge Studies. CASSS Midwest Regional Virtual Forum 2020.
32. 32.↵
    Council of Europe, Efficacy of Antimicrobial Preservation, Chapter 5.1.3. In European Pharmacopoeia (Ph. Eur.), 11th Edition, Council of Europe: Strasbourg, France, 2020.
33. 33.↵
    1. Willey J. M.,
    2. Sherwood L.,
    3. Woolverton C. J.

    Prescott's Microbiology, 8th ed.; McGraw-Hill: New York, 2011; pp 796–797.
34. 34.↵
    1. Sandle T.

    A Review of Cleanroom Microflora: Types, Trends, and Patterns. PDA J. Pharm. Sci. Technol. 2011, 65 (4), 392–403.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Nogler-Semenitz E.,
    2. Lass-Flörl C.,
    3. Nogler M.,
    4. Speer G.,
    5. Dierich M. P.

    Bacterial Contamination of Solutions for Parenteral Administration for Single- and Multiple-Dose Vials after Multiple Use in the Hospital. Wien. Med. Wochenschr. 2007, 157 (15-16), 398–401.

    OpenUrlPubMed
36. 36.↵
    1. Trautmann M.,
    2. Zauser B.,
    3. Wiedeck H.,
    4. Buttenschön K.,
    5. Marre R.

    Bacterial Colonization and Endotoxin Contamination of Intravenous Infusion Fluids. J. Hosp. Infect. 1997, 37 (3), 225–236.

    OpenUrlPubMed
37. 37.↵
    1. Matsaniotis N. S.,
    2. Syriopoulou V. P.,
    3. Theodoridou M. C.,
    4. Tzanetou K. G.,
    5. Mostrou G. I.

    Enterobacter Sepsis in Infants and Children Due to Contaminated Intravenous Fluids. Infect. Control 1984, 5 (10), 471–477.

    OpenUrlPubMedWeb of Science
38. 38.↵
    1. Maragakis L. L.,
    2. Chaiwarith R.,
    3. Srinivasan A.,
    4. Torriani F. J.,
    5. Avdic E.,
    6. Lee A.,
    7. Ross T. R.,
    8. Carroll K. C.,
    9. Perl T. M.

    Sphingomonas paucimobilis Bloodstream Infections Associated with Contaminated Intravenous Fentanyl. Emerg. Infect. Dis. 2009, 15 (1), 12–18.

    OpenUrlCrossRefPubMed
39. 39.↵
    ATCC (American Type Culture Collection). Microbe Products. https://www.atcc.org/ (accessed October 2022).
40. 40.↵
    Council of Europe. Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests, Chapter 2.6.12. In European Pharmacopoeia (Ph. Eur.), 10th Edition, Council of Europe: Strasbourg, France, 2021.
41. 41.↵
    Ministry of Health Labour and Welfare of Japan. Chapter 4.05. Microbial Examination of Non-Sterile products. In The Japanese Pharmacopoeia, 18th Edition (English Version), MHLW: Tokyo, 2021.
42. 42.↵
    U.S. Pharmacopeial Convention, General Chapter <61> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests. In USP 43–NF 38, USP: Rockville, MD, 2013.
43. 43.↵
    Ministry of Health Labour and Welfare of Japan. General Information <G4-3-170> Preservatives-Effectiveness Tests. In The Japanese Pharmacopoeia, 18th Edition (English Version), MHLW: Tokyo, 2021.
44. 44.↵
    Blincyto® (Blinatumomab) for Injection, for Intravenous Use Prescribing Information. https://www.pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/blincyto/blincyto_pi_hcp_english.pdf.
45. 45.↵
    American Society of Health-System Pharmacists (ASHP). The ASHP Discussion Guide on USP Chapter <797>. https://www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/sterile-compounding/ashp-discussion-guide-on-usp-chapter-797.pdf (accessed October 2022).
46. 46.↵
    U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA Web site. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers#what (accessed October 2022).
47. 47.↵
    U.S. Food and Drug Administration. 21CFR Section 353a. Pharmacy Compounding. U.S. Department of Health and Human Services. Government Publishing Office: Washington D.C. https://www.govinfo.gov/content/pkg/USCODE-2011-title21/pdf/USCODE-2011-title21-chap9-subchapV-partA-sec353a.pdf (accessed October 2022).
48. 48.↵
    U.S. Pharmacopeial Convention. Proposed Revisions to <797> Pharmaceutical Compounding—Sterile Preparations. https://go.usp.org/Proposed_2021_Revisions_795_797 (accessed October 2022).
49. 49.↵
    Virginia Department of Health Professions Board of Medicine. 18vac85-20-410. Requirements for Low-Risk, Medium-Risk, or High-Risk Sterile Mixing, Diluting or Reconstituting. https://www.dhp.virginia.gov/medicine/newsletters/BoardBrief89.pdf (accessed October 2022).